Profiting From The $2.4 Trillion
Biotech Revolution
7 Breakthrough Stocks Investors Need to Know About
Special opportunity ends midnight Sunday.
Special opportunity ends in .
Medical science and technology have started to advance at "warp speed."
People around the world are standing in line for hours to get a highly-effective vaccine that was developed in a matter of months. Vaccines in the past have taken years or even decades to complete.
Of course, COVID treatments get the most headlines. But that's just the tip of the iceberg.
Thanks to radical breakthroughs, we're approaching a day when no one struggles with Alzheimer's disease...
No one dies of cancer...
And no baby is ever born blind.
That day is fast approaching.
In fact, doctors now have the ability to literally edit human DNA. They're using this new technology to explore ways to eliminate our vulnerability to many diseases and genetic conditions.
An article in USA Today says it this way:
"Humans had better be ready to play God. Because we've now got the tools to do just that."
Many types of cancer, HIV/AIDS, muscular dystrophy, and even genetic blindness may soon be relegated to the pages of history books - just like polio and smallpox.
In addition to the massive leaps in our ability to transform human life and health... we also have new opportunities to invest in the cutting-edge companies that are bringing these advances into the marketplace.
The Rapid Expansion of Biotech Investing
There are more than 300 public biotechnology companies spending billions of dollars on research and development. Hundreds more innovative start-ups could be acquired or go public themselves in the near future.
All told, the industry is projected to explode beyond $2.44 trillion in size by 2028.
It's a lot to keep up with... and not every Biotech stock is worth investing in.
Senior Stock Strategist Kevin Cook has dedicated countless hours to poring over reports, studying these advancements and analyzing the companies behind them.
His ability to make sense of - and profit from - fast-moving market data is hard to match.
For 9 years, Cook worked as a market maker for the biggest banks and hedge funds in the world, trading upwards of $100 million per day.
He's also been featured on CNBC, Bloomberg and other news media.
Over the past several years, Cook's produced a strong track record of recommending lucrative investments in the Biotech space.
He released a special report in January 2020 revealing his top 7 Biotech picks for the year. Those recommendations include:
Invitae Corp., which surged +257.6% in 11 months
GW Pharmaceuticals, which soared +109.6% in 15 months after a buyout
announcement from Jazz Pharmaceuticals
Editas Medicine, which shot up +204.7% in 12 months
Sangamo Therapeutics, which blasted +119.3% in 11 months
Intellia Therapeutics, which exploded +477.1% in 12 months
With the increasing speed of developments in technologies like rapid production of vaccinations, CRISPR gene editing, immuno-oncology, and the introduction of Artificial Intelligence into medicine, there's never been a more promising time to invest in biotech companies.
According to Kevin Cook, a handful of stocks show high probability of outsized gains in the months ahead.
To give investors the chance to look into these companies before their prices surge, he created a very special report.
Introducing...
The Century of Biology: 7 Biotech Stocks to Buy Now - 3rd Edition
This report reveals the top 7 stocks our research indicates are positioned for strong upsides in 2021 and beyond. In fact, he says these stocks may give investors the chance to grow their wealth faster than anything else in the market.
In this in-depth report you'll find out about:
- A company that multiplied its revenue by 10 times in 2020... and appears on the verge of another jolt higher as it begins developing cancer vaccines...
- A fast-moving small-cap that holds several key patents, giving the company ownership of important intellectual property in the gene editing field...
- A groundbreaking firm that specializes in synthetic genes and is pioneering the use of DNA to store digital data...
- Plus 4 more stocks that could hand you triple-digit gains while significantly improving the prevention and treatment of thousands of diseases.
You'll want to be ready to pick up these stocks right away. New developments, FDA approvals and multibillion-dollar acquisitions by Big Pharma companies can cause shares to skyrocket very quickly.
As a result, you may never see these stocks priced so low again. You have a short window of time to take full advantage.
Total Cost for The Century of Biology Special Report: $1
Plus...That Same Dollar Brings You Full 30-Day Access to All Zacks Buys & Sells Through Zacks Ultimate
In other words, during your 30-day trial you can also sample:
- All our short-term trading portfolios
- All our long-term investing portfolios
- All our private market insights
- Zacks Premium research & tools
- And more
No obligation beyond $1.
You may cancel at any time.
Using Zacks Rank Profit Power
All of our portfolios — from value and growth, to stable income and ETFs — — from value to growth, from stable income to ETFs — are grounded in Zacks Rank fundamentals.
This unbiased, mathematical system has more than doubled the S&P 500's average yearly gain. Even through three recessions and many corrections, it has averaged +24.2% per year.
Let's suppose you had invested $10,000 in the S&P 500 in 1988. Rebalancing monthly and not counting fees, you would have more than $450,000 today.
But if you had put that same $10,000 into the Zacks Rank system, it could have compounded to more than $26.0 million dollars.
228 Double and Triple-Digit Gains Last Year and Already 88 More in 2024
While not all picks can be winners, every one of our portfolio recommendation services was designed to identify those with the highest probability of success.
Here are some past winners from our short-term trading portfolios¹:
- +190.2% on EXp World Holdings from Blockchain Innovators
- +319.3% on Cencora from Options Trader
- +121.0% on Super Micro Computer from Technology Innovators
- +86.7% on Tenet Healthcare from Insider Trader
- +131.9% on C3.Ai, Inc. from Counterstrike
- +59.8% on International Seaways from Surprise Trader
- +67.9% on MacroGenics from Healthcare Innovators
- +475.0% on NVIDIA from TAZR Trader
And several past winners from our long-term investing portfolios¹:
- +129.3% on Rover Group from Stocks Under $10
- +123.2% on Global X IoT ETF from Income Investor
- +200.3% on E.L.F. Beauty from Home Run Investor
- +124.8% on Archer Daniels Midland from Value Investor
- +107.3% on Shopify from Zacks Top 10 Stocks
Important: Deadline to Download Century of Biology is Sunday
Get Senior Stock Strategist Kevin Cooks top 7 stocks to buy to profit from the $2.4 trillion biotech revolution. Each of these picks could generate explosive gains in the coming months.
Valued at $99, it is yours free when you start your 30-day trial.
Questions? Call toll-free at 1.888.775.8348 M-F, 10 am - 6 pm ET. Outside the U.S., 1.312.265.9309.
+Or click here for Frequently Asked Questions about this Zacks Ultimate opportunity.
What happens after my 30-day Zacks Ultimate trial is over?
You'll be notified at least seven days before your trial ends. You can choose to:
- Simply walk away and owe us nothing. We'll be sorry to see you go, but we mean it when we say beyond $1 there is no obligation.
- Let your Zacks Ultimate membership continue for only $299 per month.
- Join this service and/or any of the individual portfolios.
Are there money-back guarantees?
You are backed with two assurances. The first is a Guarantee of Satisfaction. You may cancel up to 90 days after your $1 trial is over and if the service has not exceeded your expectations, then your money will be refunded - including the $1 you paid for the trial.
You will also be protected by a full-year, money-back Performance Guarantee. Details. That means if we don't help you beat the market, we'll refund your subscription.
What portfolios are included in Zacks Ultimate?
You gain real-time access to buys, sells, and market commentary from all of these private services:
- Black Box Trader Automated stock-picking formula distills 10 high-potential performers from thousands of stocks each week.
- Blockchain Innovators Zacks pursues massive gains from the emerging "Internet of Money" without the breakneck volatility of speculating in cryptocurrencies.
- Commodity Innovators seeks both short and long-term profits on oil, gold, livestock, grains, currencies, and more at reduced risk. No futures or options, just easy-to-trade stocks and ETFs.
- Counterstrike When High-Frequency Traders trigger panic sell-offs of good stocks, Zacks targets the best of them as they rebound.
- ETF Investor Blending Zacks Industry Rank and its 2-to-1 performance advantage with the Zacks ETF Rank, it rides emerging trends without added risk from buying stocks individually.
- Headline Trader Fast-reflex portfolio gives you the jump on breaking news that ignites big stock moves. It focuses on companies that already show strong fundamentals and rising earnings estimates.
- Healthcare Innovators Tracks breakthroughs in the pipeline throughout the healthcare sector - including pharmaceuticals, biotechnology, devices, hospitals, and more.
- Home Run Investor Targets under-the-radar companies with over-the-top +50%, +100%, +200% potential. But it's watchful to prevent strike outs by cutting losers and providing diversity.
- Income Investor Balances more aggressive moves with a steady flow of income through selected high-dividend stocks, plus other low-risk assets that offer higher potential than fixed income.
- Insider Trader When significant insiders buy their own company's stock with their own money, it's an excellent signal - especially when combined with strong Zacks Rank timeliness and valuation factors.
- Large-Cap Trader Selected large-cap stocks offer greater resistance to volatility than small caps, and yet can fly under-the-radar with strong growth potential.
- Options Trader Blends the +24.2% yearly gain power of the Zacks Rank with professional options strategies to pursue substantial returns at a fraction of what would be risked on regular stock purchases.
- Short List Non-biased, computer-driven list of stocks primed to fall much more than average, making them excellent candidates for shorting - especially in bear markets.
- Stocks Under $10 Pinpoints low-priced stocks with improving fundamentals and earnings outlooks for exceptional growth potential.
- Surprise Trader Zacks' research breakthrough isolates the most accurate analyst "whispers" to call positive earnings surprises before they're reported with over 80% accuracy.
- TAZR Technical Analysis + Zacks Rank blends the best of both worlds to catch a manageable handful of #1 and #2 stocks at the right time.
- Technology Innovators Tracks emerging trends and breakthrough companies in fast-growing fields such as artificial intelligence, cloud computing, the Internet of Things, and more.
- Value Investor Combining proven value criteria with Zacks Rank timing, it tracks undervalued companies until the market starts to see their real worth.
- Zacks Confidential Each week, Zacks Executive VP Kevin Matras spotlights key trades and commentary from one of our hottest strategists so you can see Zacks' Best of the Best.
- Zacks Premium Provides professional-grade tools to individual investors, featuring daily updates of the Zacks Rank, full access to Zacks Equity Research, Focus List portfolio of 50 stocks for the long haul, Premium Screens and much more.
- Zacks Top 10 Stocks Compiles the best 10 stocks to buy and hold throughout the year. Each pick comes with in-depth research, and is actively managed with quarterly updates.
Will following all Zacks portfolio recommendations be hard work or "too much information?"
Not at all - most members start by quickly scanning each of the portfolios, and then simply narrow them down to the one(s) that suit them best.
Also, each day you receive a summary email that spotlights intraday trades and key market commentary from the various services.
And if you have any questions or need any help sorting out which portfolios are best for you, just pick up the phone and talk to a real person who can give you the info you need.
Ready to get started?
Since 2011, tens of thousands have taken advantage of this 30-day see-all experience. Don't miss this opportunity to discover the impact that the Zacks Rank can have on your portfolio.
It only costs $1. And not 1 cent of further obligation.